Lausanne, Switzerland, November 4, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback